{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:31:31Z","timestamp":1787236291078,"version":"build-2736575974"},"reference-count":7,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Digestion"],"published-print":{"date-parts":[[2008]]},"abstract":"<jats:p>Background: Up to the present date, the treatment of recurrent chronic fistulas occurring with Crohn\u2019s disease represents a challenging task for both internists and surgeons alike. Methods: Conservative methods of treatment using steroids, dietotherapy, antibiotics or immunosuppressive agents are not particularly effective in treating fistulas. Treatment with anti-tumor necrosis factor-\u03b1 (TNF\u03b1) antibodies results in more remissions of fistulas. However, its use requires appropriate medical experience and causes substantial costs. Surgical procedures such as fistula sanitation or protective ileostomy are often obfuscated by the recurrence of the condition. The efficiency of anti-TNF\u03b1 antibodies for the treatment of active Crohn\u2019s disease has been evidenced through several multicenter, double-blind, placebo-controlled studies. Results: Here we report the successful anti-TNF\u03b1 treatment of a patient suffering from chronic, fistulizing, therapy-resistant Crohn\u2018s disease and a concomitant chronic autoimmune thrombocytopenia. The chimeric anti-TNF\u03b1 antibody infliximab markedly reduced the disease activity of Crohn\u2019s disease, and, in addition, substantially increased the platelet counts. After infliximab application, no other treatment of autoimmune thrombocytopenia was required. After infliximab therapy, autoantibodies to dsDNS could be observed. However, there were no signs of a lupus-like disease. Conclusion: This report indicates a favorable therapeutic response of autoimmune thrombocytopenia associated to Crohn\u2019s disease.<\/jats:p>","DOI":"10.1159\/000187637","type":"journal-article","created":{"date-parts":[[2008,12,22]],"date-time":"2008-12-22T07:10:11Z","timestamp":1229929811000},"page":"195-200","source":"Crossref","is-referenced-by-count":11,"title":["Long-Term Partial Remission of AutoImmune Thrombocytopenia in a Patient Treated with the Anti-Tumor Necrosis Factor-Alpha Antibody Infliximab for Refractory Fistulizing Crohn\u2019s Disease"],"prefix":"10.1159","volume":"78","author":[{"given":"Thomas M.","family":"de Rossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard E.","family":"Voll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"N\u00e4gel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Weidenhiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Konturek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eckhart G.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Raithel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2008,12,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJM199808063390610"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097%2F01.MIB.0000188503.00770.8c"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007%2Fs001080050721"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016%2F0952-7915%2893%2990107-4"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007%2Fs001080050723"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1053%2Fgast.2001.28674"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002%2Fajh.10331"}],"container-title":["Digestion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/dig\/article-pdf\/78\/4\/195\/4033656\/000187637.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/dig\/article-pdf\/78\/4\/195\/4033656\/000187637.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T20:34:18Z","timestamp":1745440458000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000187637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008]]},"references-count":7,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2009,2,1]]},"published-print":{"date-parts":[[2008,4,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000187637","archive":["Portico"],"relation":{},"ISSN":["0012-2823","1421-9867"],"issn-type":[{"value":"0012-2823","type":"print"},{"value":"1421-9867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008]]}}}